• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Karuna Therapeutics Inc (NQ: KRTX )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Karuna Therapeutics Inc

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Beyond Tech And AI: Why The Sector Hedge Funds Prefer Is Not The One You'd Expect
    Hedge funds are shifting towards stability and value by favoring the health care sector over booming tech stocks. 
    Via Benzinga
    Karuna Therapeutics: Q4 Earnings Insights
    Via Benzinga
    Karuna Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides General Business Update
    From Karuna Therapeutics, Inc.
    Via Business Wire
    Mental Health Mavericks: 3 Stocks Changing the Game
    Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money. 
    Via InvestorPlace
    This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
    Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion across epilepsy and mood disorders. Anticipate significant developments in lead asset... 
    Via Benzinga
    Mizuho Downgrades Karuna Therapeutics: Here's What You Need To Know
    Via Benzinga
    KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX
    From Kahn Swick & Foti, LLC
    Via Business Wire
    UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
    UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy. 
    Via Benzinga
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Catalent, Inc. (NYSE – CTLT), Everbridge, Inc. (Nasdaq – EVBG), Slam Corp. (Nasdaq – SLAM), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AVROBIO, Inc. (Nasdaq – AVRO), California BanCorp (Nasdaq – CALB), Exro Technologies Inc. (OTC – EXROF), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq – KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    ABBV: This Top Biotech Just Went On A Buying Spree
    AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel). 
    Via Talk Markets
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Karuna Therapeutics, Inc. (Nasdaq – KRTX), Carrols Restaurant Group, Inc. (Nasdaq - TAST), Ansys, Inc. (Nasdaq - ANSS), HomeStreet, Inc. (Nasdaq - HMST)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Bullish Continuation In '24? 3 Market Areas To Watch
    This article discusses 3 market areas that should outperform dramatically over the next 12 months... 
    Via Talk Markets
    5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
    The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even more interesting. 
    Via Benzinga
    Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
    Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
    Via Investor's Business Daily
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTX
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
    Bristol Myers announced two acquisitions in a week. The pharma giant is boosting its neuroscience pipeline with Karuna and its oncology pipeline with RayzeBio. 
    Via MarketBeat
    Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
    The major indexes boast big annual gains with the Dow at record highs. 
    Via Investor's Business Daily
    Topics Stocks
    Exposures US Equities
    Microsoft To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Thursday
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
    Via Benzinga
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RayzeBio, Inc. (Nasdaq – RYZB), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Daseke, Inc. (Nasdaq – DSKE), Karuna Therapeutics, Inc. (Nasdaq – KRTX)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Bristol-Myers' Acquisition Of Karuna Therapeutics Paves Way For Aggressive Global Marketing Of KarXT: Analyst
    H.C. 
    Via Benzinga
    Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%
    Bristol Myers Squibb said it would acquire cancer drug developer RayzeBio in a $4.1 billion deal. RYZB stock soared; BMY stock traded slightly lower. 
    Via Investor's Business Daily
    Why Is RayzeBio (RYZB) Stock Up 100% Today?
    RYZB stock has doubled today after Bristol Myers Squibb shelled out $4.1 billion to buy RayzeBio. Expect more such deals in 2024. 
    Via InvestorPlace
    Cognizant Technology Solutions To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Tuesday
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Bristol-Myers Buying Karuna Signals A Biotech Boom Ahead: Jefferies
    Bristol-Myers Squibb is buying Karuna Therapeutics for $14 billion. Karuna Therapeutics Inc stock jumped nearly 50% on Friday. Jefferies analyst Michael Yee shares his view on biotech stocks. 
    Via Talk Markets
    Dow Edges Lower; Nike Sales Miss Estimates
    U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Friday. The Dow traded down 0.05% to 37,385.32 while the NASDAQ rose 0.12% to 14,982.36. The S&P 500 also... 
    Via Benzinga
    Topics Earnings Stocks
    Exposures Financial US Equities
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.